Author

Andrew W. Michell

Observed names: A Michell, A W Michell, A. Michell, A. W. Michell, A.W. Michell, Andrew MICHELL, Andrew Michell, Andrew W Michell, Michell, Andrew W.

Institutions: Addenbrooke's Hospital, NIHR Cambridge Biomedical Research Centre

Observed institutions: University of Cambridge, Rosie Hospital, Cambridge University Hospitals NHS Foundation Trust, University of Oxford, National Hospital for Neurology and Neurosurgery, Addenbrooke's Hospital, NIHR Cambridge Biomedical Research Centre, UCL Queen Square Institute of Neurology, Imperial College London

OpenAlex ID: A5104440254

Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis

2010 · Sarosh R. Irani, Andrew W. Michell, et al. · Annals of Neurology · 928

Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study

2012 · Peter Connick, Madhan Kolappan, et al. · The Lancet Neurology · 607

PDF

Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles

2006 · Benjamin R. Underwood, David Broadhurst, et al. · Brain · 183

PDF

Biomarkers and Parkinson's disease

2004 · A. W. Michell · Brain · 183

The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments

2011 · Peter Connick, Madhan Kolappan, et al. · Trials · 119

PDF

Saccadic latency distributions in Parkinson’s disease and the effects of l-dopa

2006 · A. W. Michell, Z. Xu, et al. · Experimental Brain Research · 106

Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study

2021 · J William L Brown, Nick G Cunniffe, et al. · The Lancet Neurology · 100

Metabolomic analysis of urine and serum in Parkinson’s disease

2008 · Andrew W. Michell, David Mosedale, et al. · Metabolomics · 97

Skin and platelet α-synuclein as peripheral biomarkers of Parkinson's disease

2005 · Andrew W. Michell, Leila M. Luheshi, et al. · Neuroscience Letters · 92

Brain injury in COVID-19 is associated with dysregulated innate and adaptive immune responses

2022 · Edward J Needham, Alexander L Ren, et al. · Brain · 90

PDF

Mononeuritis multiplex: an unexpectedly frequent feature of severe COVID-19

2020 · Edward Needham, Virginia Newcombe, et al. · Journal of Neurology · 78

PDF

The Effect of Truncated Human α-Synuclein (1–120) on Dopaminergic Cells in a Transgenic Mouse Model of Parkinson's Disease

2007 · A. W. Michell, G. K. Tofaris, et al. · Cell Transplantation · 63

Mapping cortical haemodynamics during neonatal seizures using diffuse optical tomography: A case study

2014 · Harsimrat Singh, Robert J. Cooper, et al. · NeuroImage Clinical · 55

PDF

The use of quantitative oculometry in the assessment of Huntington’s disease

2005 · F. R. Ali, A. W. Michell, et al. · Experimental Brain Research · 51

Central pontine myelinolysis temporally related to hypophosphataemia

2003 · A W Michell · Journal of Neurology Neurosurgery & Psychiatry · 50

PDF

Hand tapping: A simple, reproducible, objective marker of motor dysfunction in Huntington’s disease

2008 · A. W. Michell, A. O. G. Goodman, et al. · Journal of Neurology · 43

GJB1 gene mutations in suspected inflammatory demyelinating neuropathies not responding to treatment

2009 · A W Michell, M Laura, et al. · Journal of Neurology Neurosurgery & Psychiatry · 42

A case of late onset sporadic Parkinson's disease with an A53T mutation in -synuclein

2005 · A W Michell · Journal of Neurology Neurosurgery & Psychiatry · 41

PDF

Transient haemodynamic events in neurologically compromised infants: A simultaneous EEG and diffuse optical imaging study

2011 · R.J. Cooper, Jeremy C. Hebden, et al. · NeuroImage · 39

Hemodynamic response to burst-suppressed and discontinuous electroencephalography activity in infants with hypoxic ischemic encephalopathy

2016 · Maria Chalia, Chuen Wai Lee, et al. · Neurophotonics · 35

PDF

Long-term remission with rituximab in refractory leucine-rich glioma inactivated 1 antibody encephalitis

2014 · J. William L. Brown, Peter J. Martin, et al. · Journal of Neuroimmunology · 32

Biomarkers in Huntington's and Parkinson's Disease

2009 · Gráinne C. O’Keeffe, Andrew W. Michell, et al. · Annals of the New York Academy of Sciences · 31

Lewy bodies in Parkinson's disease: Protectors or perpetrators?

2005 · Timothy P. Harrower, Andrew W. Michell, et al. · Experimental Neurology · 31

Remyelination in humans due to a retinoid‐X receptor agonist is age‐dependent

2022 · Christopher E. McMurran, Trisha Mukherjee, et al. · Annals of Clinical and Translational Neurology · 21

Parkinson's disease – the continuing search for biomarkers

2011 · David P. Breen, Andrew W. Michell, et al. · Clinical Chemistry and Laboratory Medicine (CCLM) · 21

Works count: 78

Citation count: 3,272

H-index: 23

I10-index: 31